Showing 1 - 20 results of 23 for search 'E. S. Kropacheva', query time: 0.09s Refine Results
  1. 1
    SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS

    SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS by E. S. Kropacheva

    Published 2016-01-01
    Get full text
    Article
  2. 2
    SAFETY ISSUES IN THE TREATMENT OF PATIENTS TAKING DABIGATRAN

    SAFETY ISSUES IN THE TREATMENT OF PATIENTS TAKING DABIGATRAN by E. S. Kropacheva

    Published 2016-07-01
    Get full text
    Article
  3. 3
    SAFETY OF THERAPY AND PATRONAGE SYSTEM IN PATIENTS WHO RECEIVE WARFARIN

    SAFETY OF THERAPY AND PATRONAGE SYSTEM IN PATIENTS WHO RECEIVE WARFARIN by E. S. Kropacheva

    Published 2015-12-01
    Get full text
    Article
  4. 4
    Intracardiac thrombosis: frequency, risk factors and place of oral anticoagulants in treatment

    Intracardiac thrombosis: frequency, risk factors and place of oral anticoagulants in treatment by E. S. Kropacheva

    Published 2020-06-01
    Get full text
    Article
  5. 5
    SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS

    SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS by E. S. Kropacheva

    Published 2016-01-01
    Get full text
    Article
  6. 6
    SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP

    SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP by E. S. Kropacheva, E. P. Panchenko

    Published 2017-05-01
    Get full text
    Article
  7. 7
    The place of dabigatran in the treatment of patients with atrial fibrillation in the light of modern recommendations

    The place of dabigatran in the treatment of patients with atrial fibrillation in the light of modern recommendations by E. S. Kropacheva, E. P. Panchenko

    Published 2023-08-01
    Get full text
    Article
  8. 8
    Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran

    Aspects of anticoagulant therapy in patients with atrial fibrillation in the light of updated guidelines of the European society of cardiology 2020: the position of dabigatran by E. S. Kropacheva, E. P. Panchenko

    Published 2020-12-01
    Get full text
    Article
  9. 9
    ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION

    ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION by O. A. Zemlyanskaya, E. S. Kropacheva

    Published 2019-06-01
    Get full text
    Article
  10. 10
    Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA))

    Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA)) by E. S. Kropacheva, E. N. Krivosheeva, E. P. Panchenko

    Published 2021-07-01
    Get full text
    Article
  11. 11
    Renal function in patients receiving long-term warfarin therapy: A five-year prospective follow-up

    Renal function in patients receiving long-term warfarin therapy: A five-year prospective follow-up by O A Zemlyanskaya, E S Kropacheva, A B Dobrovolsky, E P Panchenko

    Published 2017-09-01
    Get full text
    Article
  12. 12
    CLINICAL FACTORS AND ANTICOAGULATION LEVEL THAT DETERMINE THE SUDDEN LOSS OF KIDNEY FUNCTION IN PATIENTS LONG-TAKING WARFARIN (A 5-YEAR PROSPECTIVE, OBSERVATIONAL STUDY)

    CLINICAL FACTORS AND ANTICOAGULATION LEVEL THAT DETERMINE THE SUDDEN LOSS OF KIDNEY FUNCTION IN PATIENTS LONG-TAKING WARFARIN (A 5-YEAR PROSPECTIVE, OBSERVATIONAL STUDY) by E. S. Kropacheva, O. A. Zemlyanskaya, A. В. Dobrovolsky, Е. P. Panchenko

    Published 2018-05-01
    Get full text
    Article
  13. 13
    THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a prospective 10-year follow-up study)

    THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a pr... by E. S. KROPACHEVA, O. A. ZEMLYANSKAYA, A. B. DOBROVOLSKY, E. P. PANCHENKO

    Published 2017-12-01
    Get full text
    Article
  14. 14
    Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interventions

    Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interve... by A I Loginova, E S Kropacheva, E B Maykov, T V Balakhonova, S P Golitsyn

    Published 2019-09-01
    Get full text
    Article
  15. 15
    Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)

    Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembo... by A. I. Mironova (Staroverova), E. P. Panchenko, E. S. Kropacheva, O. A. Zemlyanskaya

    Published 2020-10-01
    Get full text
    Article
  16. 16
    Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve

    Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve by A. I. Staroverova, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko

    Published 2023-08-01
    Get full text
    Article
  17. 17
    SAFETY OF LONG-TERM THERAPY WITH WARFARIN: HEMORRHAGE FREQUENCY AND CLINICAL PREDICTORS (results of a prospective 15-year follow-up)

    SAFETY OF LONG-TERM THERAPY WITH WARFARIN: HEMORRHAGE FREQUENCY AND CLINICAL PREDICTORS (results of a prospective 15-year follow-up) by E. S. Kropacheva, O. A. Zemlyanskaya, E. P. Panchenko, A. B. Dobrovolsky, E. N. Krivosheeva

    Published 2017-05-01
    Get full text
    Article
  18. 18
    Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants

    Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants by A. I. Mironova, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko

    Published 2022-06-01
    Get full text
    Article
  19. 19
    Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention

    Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention by E. N. Krivosheeva, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko

    Published 2021-08-01
    Get full text
    Article
  20. 20
    Diagnostic and prognostic significance of D-dimer in internal medicine

    Diagnostic and prognostic significance of D-dimer in internal medicine by Yu A Fedotkina, А В Dobrovobky, E S Kropacheva, E V Titaeva, E P Panchenko

    Published 2003-12-01
    Get full text
    Article

Search Tools: